Clinical Trial: NCT03820063
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Borstkanker Onderzoek Groep |
| Information Provided By: | Borstkanker Onderzoek Groep |
| Last Update Posted: | 2026-10-05 |
Study Overview
Brief Summary
This is a multicenter, single arm, phase II study evaluating the efficacy of image-guided de-escalating neoadjuvant treatment with paclitaxel, Herceptin® (trastuzumab), carboplatin, and pertuzumab (PTC-Ptz) in stage II-Ill HER2-positive breast cancer.
Official Title
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Conditions
Breast Cancer
Intervention / Treatment
- Drug: PTC-Pz
Other Study ID Numbers
- BOOG 2018-01
Start Date (Actual)
2019-02-27
Primary Completion Date (Actual)
2022-11-15
Study Completion Date (Estimated)
2032-05-01
Enrollment (Estimated)
462
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Borstkanker Onderzoek Groep |
| Information Provided By: | Borstkanker Onderzoek Groep |
| Last Update Posted: | 2026-10-05 |
Study Overview
Brief Summary
This is a multicenter, single arm, phase II study evaluating the efficacy of image-guided de-escalating neoadjuvant treatment with paclitaxel, Herceptin® (trastuzumab), carboplatin, and pertuzumab (PTC-Ptz) in stage II-Ill HER2-positive breast cancer.
Official Title
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Conditions
Breast Cancer
Intervention / Treatment
- Drug: PTC-Pz
Other Study ID Numbers
- BOOG 2018-01
Start Date (Actual)
2019-02-27
Primary Completion Date (Actual)
2022-11-15
Study Completion Date (Estimated)
2032-05-01
Enrollment (Estimated)
462
Study Type
Interventional
Phase
Phase 2